Drug intelligence / Profile preview

AV0113

Development stage: Unknown
Lead developer: AOP Health
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intranodal

Overview

AV0113 is an autologous dendritic cell-based cancer immunotherapy vaccine developed by Activartis Biotech. It utilizes a patented technology that combines patient-specific tumor antigens (derived from tumor cell lysates) with bacterial endotoxins as danger signals to activate monocyte-derived dendritic cells. These activated cells are designed to prime type 1 T helper cells, thereby stimulating a cytolytic anti-tumor immune response. While initially studied in glioblastoma, AV0113 has been evaluated in Phase 1 clinical trials for pediatric patients with refractory solid tumors, including bone and soft tissue sarcomas.

Other names: AV0113 DC-CITAV-0113 DC-CITAV 0113 DC-CIT

Targets

TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on AV0113.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AV0113.

Explore the full profile